Successful translational R&D needs equity ownership

12/6/2012 | Forbes

Early-stage translational research and development projects in life sciences are likely to fall flat in the absence of equity ownership in startup companies, writes Atlas Venture partner Bruce Booth. Equity ownership "rewards the successful entrepreneur and binds them together with the academic founders, key advisors, and the broader shareholders," he writes. Equity rewards risk-takers and entrepreneurs, thus encouraging investment, he writes.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR